# The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

> **NCT00911157** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 39 (actual)

## Conditions studied

- Thrombosis, Venous

## Interventions

- **DRUG:** Fondaparinux sodium
- **DRUG:** unfractionated heparin (UFH)

## Key facts

- **NCT ID:** NCT00911157
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00911157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00911157, "The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00911157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*